Host:Dr. Manuj AgarwalCo-Founder, Prostate Cancer Institute of America Guest:Dr. Aman Taggar, MDRadiation Oncologist, Odette Cancer Center, Sunnybrook Health Science CenterTwitter/X: @dramantaggar In this episode, Dr. Manuj Agarwal interviews Dr. Aman Taggar about the ASCENDE-SBRT trial, a study comparing SBRT and brachytherapy as boost techniques for intermediate- and high-risk prostate cancer. The trial builds on the ASCENDE-RT study, with a focus on refining treatment plans, including considerations for focal boost and androgen deprivation. Dr. Taggar explains the reasoning behind including both LDR and HDR brachytherapy in the trial and shares insights into the use of I-125 and Pd-103 isotopes in the LDR arm. Key Discussion Points: Differences between ASCENDE-RT and ASCENDE-SBRT. Focal boost techniques and treatment margin considerations. The inclusion of both LDR and HDR brachytherapy and the potential impact on data. For more information on the PR.24 trial discussed in this episode, visit the PR.24 trial page.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related